Targeting tumor necrosis factor receptors in ankylosing spondylitis

Annals of the New York Academy of Sciences
Michal LataChuan-Ju Liu

Abstract

Over the past two decades, considerable advances in our understanding of inflammatory and immune pathways have allowed for the growing use of targeted biologic therapy. Most notably, the introduction of tumor necrosis factor (TNF) inhibitors has dramatically changed the management of autoimmune inflammatory disorders, including ankylosing spondylitis (AS). Despite the efficacy of TNF inhibitors documented in multiple clinical trials, anti-TNF therapy in AS is far from foolproof; it is associated with serious adverse effects and limited response to therapy in some patients. Moreover, specific questions regarding the role of TNF as a mediator of AS remain unanswered. Therefore, additional efforts are needed in order to better understand the role of TNF in the pathogenesis of AS and to develop safer and more effective treatment strategies. The purpose of this review is to better the understanding of the physiologic and pathogenic roles of TNF signaling in the course of AS. Relevant TNF biology and novel approaches to TNF blockade in AS are discussed.

References

Dec 1, 1994·The Journal of Experimental Medicine·J D TaurogR E Hammer
Feb 12, 2000·European Journal of Immunology·F K Chan, M J Lenardo
May 29, 2000·Human Immunology·Z RehákováS Weinreich
Jul 4, 2001·The Journal of Clinical Investigation·S RyuD L Faustman
Mar 19, 2002·Cellular Signalling·David J MacEwan
Mar 16, 2004·Current Rheumatology Reports·John D Reveille
Dec 31, 2004·American Journal of Physiology. Endocrinology and Metabolism·Linda C GilbertMark S Nanes
Dec 24, 2005·The Journal of Biological Chemistry·Hiroyuki KanekiLianping Xing
Jan 24, 2007·Nature Medicine·Danielle DiarraGeorg Schett
Sep 30, 2008·Arthritis and Rheumatism·Désirée van der HeijdeUNKNOWN Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group
Oct 18, 2008·Journal of Neuroinflammation·Melissa K McCoy, Malú G Tansey
Dec 19, 2008·Cytokine·Megumi Funakoshi-TagoTadashi Kasahara
Aug 26, 2009·Arthritis Research & Therapy·Désirée van der HeijdeUNKNOWN ATLAS study group
May 22, 2010·Nature Reviews. Drug Discovery·Denise Faustman, Miriam Davis
Jun 3, 2010·Nature Reviews. Rheumatology·Lai-Shan TamDavid Yu
Jul 12, 2011·Current Rheumatology Reports·Liesbet Van PraetDirk Elewaut
Oct 4, 2011·Cytokine & Growth Factor Reviews·Filip Van HauwermeirenClaude Libert
Oct 20, 2011·Pharmacology & Therapeutics·Chuan-ju Liu, Xavier Bosch
Jan 26, 2012·Arthritis Care & Research·John D ReveilleMichael H Weisman
Oct 23, 2012·Cancer Letters·Wen-Ming Chu
Oct 24, 2012·Journal of Leukocyte Biology·Jinlong JianChuanju Liu
Dec 26, 2012·Biochemical and Biophysical Research Communications·A BriolayD Magne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.